Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$834.4M
58M shares
52-week range
$12.72 – $16.74
43% from low
Exchange
NASDAQ
CS
P/S (TTM)
2.3
EV / FCF (TTM)
5.3
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
www.inmodemd.comNo one on the platform currently holds INMD.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,586,218 | $35.4M |
| Execution date | Ratio |
|---|---|
| 2021-10-01 | 2-for-1 |
No one on the platform has traded INMD yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 18.4% | 30.5% | 80.3% | — | — | — |
| Rev. Growth % | -6.2% | 12.4% | ||||
| Profit Margin % | 25.3% | 38.6% | 30.9% | |||
| Free Cash Flow Margin % | 22.7% | 36.0% | 33.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -6.2% on the P/E track.
At today's price, your expected annual return is +2.8% on the P/E track.
At today's price, your expected annual return is +11.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $370M | +0.6% | $1.30 | $1.27–$1.31 | 11.1× | 3 |
| 2027 | $378M | +2.0% | $1.37 | $1.21–$1.43 | 10.5× | 5 |
| 2028 | $389M | +2.9% | $1.45 | $1.17–$1.77 | 10.0× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $0.35 | $0.35 | +1.2% |
| 2026-05-06 | $0.30 | $0.25 | -16.1% |
| 2026-02-10 | $0.42 | $0.46 | +10.5% |
| 2025-11-05 | $0.35 | $0.38 | +8.3% |
| 2025-07-30 | $0.43 | $0.47 | +9.3% |
| 2025-04-28 | $0.33 | $0.31 | -6.1% |
| 2025-02-04 | $0.50 | $0.42 | -16.0% |
| 2024-10-30 | $0.63 | $0.70 | +11.1% |
| $539M |
| — |
| IARTIntegra LifeSciences Holdings Corporation | $15.59 | +2.43% | $1.2B | — |
| IRMDIRadimed Corporation | $82.46 | +0.41% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$INMD InMode Ltd. (INMD) reports that an unsolicited, non-binding acquisition proposal from M.N. Business Strategy Ltd., originally submitted to InMode’s Board of Directors on June 17, 2026, expired on September 15, 2026 in accordance with its terms. InMode states that it has not entered into any agreement with M.N. Business Strategy Ltd. regarding this proposal or any other transaction. The report is signed by Chief Financial Officer Moshik Itzkovich on behalf of the company.
View on StockTwits ↗
$INMD https://www.prnewswire.com/news-releases/inmode-advances-rf-microneedling-comfort-with-the-launch-of-morpheus8-cool-302872766.html
View on StockTwits ↗$INMD https://www.prnewswire.com/news-releases/a-wave-of-weight-loss-drugs-is-quietly-creating-a-multi-billion-dollar-opportunity-that-aesthetic-medicine-is-racing-to-capture-302866509.html
View on StockTwits ↗
$INMD clown. this is dead. sell and move on
View on StockTwits ↗
$INMD Moshe is trying to sell this for cheap like $12 or less the stock keeps going down DOMA and Steele were denied
View on StockTwits ↗$INMD no news from Steele, DOMA, I think they realize Moshe can’t be stopped and in Sept will sell for cheap
View on StockTwits ↗$INMD Moshe is trying to buy company for dirt cheap even lower than $16 a share now that Israel govt denied Steele Who can stop Moshe now?
View on StockTwits ↗
$INMD Moshe is free to sell company for any price he wants now
View on StockTwits ↗$INMD MOSHE is taking company for private for like $15-16 a share screwing shareholders this always happens with Israeli companies Inmode Haifa District Court Denied Sp Strategic Holdings' Request For Temporary Injunctive Relief In Its Entirety
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.